Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Core Insights - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [3] - The company will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference from November 11-13, 2025 [1][2] - The lead candidate, NXC-201, is a BCMA-targeted CAR-T cell therapy currently being evaluated in a U.S. multi-center study for relapsed/refractory AL Amyloidosis [3] Company Overview - Immix Biopharma, Inc. is listed on Nasdaq under the ticker IMMX [3] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3] - Interim results for NXC-201 were presented at ASCO 2025, indicating ongoing clinical evaluation [3] Investor Engagement - The company will be available for one-on-one meetings during the Stifel conference, encouraging interested investors to contact their Stifel representative [2] - A replay of the presentation will be accessible on the Immix website under the Investors section [2]